B-cell targeting in rheumatoid arthritis and other autoimmune diseases

被引:388
作者
Edwards, JCW [1 ]
Cambridge, G [1 ]
机构
[1] UCL, Dept Med, London W1P 6DB, England
关键词
D O I
10.1038/nri1838
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
B-cell-targeted therapy for autoimmune disease emerged from theoretical proposition to practical reality between 1997 and 1998, with the availability of the B-cell-depleting monoclonal antibody rituximab. Since then, a score of autoantibody-associated disorders have been treated, with most convincing evidence of efficacy seen in subjects with rheumatoid arthritis. Several classes of B-cell-targeted agent are now under investigation. From the outset, a major goal of B-cell targeting has been the re-establishment of some form of immunological tolerance. In some subjects, the observed improvement of disease for years following therapy fuels hope that this goal might ultimately be achievable.
引用
收藏
页码:394 / 403
页数:10
相关论文
共 101 条
  • [1] Abrahams VM, 2000, ARTHRITIS RHEUM-US, V43, P608, DOI 10.1002/1529-0131(200003)43:3<608::AID-ANR18>3.0.CO
  • [2] 2-G
  • [3] LJP 394 for the prevention of renal flare in patients with systemic lupus erythematosus -: Results from a randomized, double-blind, placebo-controlled study
    Alarcón-Segovia, D
    Tumlin, JA
    Furie, RA
    McKay, JD
    Cardiel, MH
    Strand, V
    Bagin, RG
    Linnik, MD
    Hepburn, B
    [J]. ARTHRITIS AND RHEUMATISM, 2003, 48 (02): : 442 - 454
  • [4] New treatments for SLE: cell-depleting and anti-cytokine therapies
    Anolik, JH
    Aringer, M
    [J]. BEST PRACTICE & RESEARCH IN CLINICAL RHEUMATOLOGY, 2005, 19 (05): : 859 - 878
  • [5] The relationship of FcγRIIIa genotype to degree of B cell depletion by rituximab in the treatment of systemic lupus erythematosus
    Anolik, JH
    Campbell, D
    Felgar, RE
    Young, F
    Sanz, I
    Rosenblatt, J
    Looney, RJ
    [J]. ARTHRITIS AND RHEUMATISM, 2003, 48 (02): : 455 - 459
  • [6] Anti-CD20 monoclonal antibody (rituximab) in the treatment of pemphigus
    Arin, MJ
    Engert, A
    Krieg, T
    Hunzelmann, N
    [J]. BRITISH JOURNAL OF DERMATOLOGY, 2005, 153 (03) : 620 - 625
  • [7] NOD2/CARD15, TLR4 and CD14 mutations in Scottish and Irish Crohn's disease patients: evidence for genetic heterogeneity within Europe?
    Arnott, IDR
    Nimmo, ER
    Drummond, HE
    Fennell, J
    Smith, BRK
    MacKinlay, E
    Morecroft, J
    Anderson, N
    Kelleher, D
    O'Sullivan, M
    McManus, R
    Satsangi, J
    [J]. GENES AND IMMUNITY, 2004, 5 (05) : 417 - 425
  • [8] Generation and characterization of LymphoStat-B, a human monoclonal antibody that antagonizes the bioactivities of B lymphocyte stimulator
    Baker, KP
    Edwards, BM
    Main, SH
    Choi, GH
    Wager, RE
    Halpern, WG
    Lappin, PB
    Riccobene, T
    Abramian, D
    Sekut, L
    Sturm, B
    Poortman, C
    Minter, RR
    Dobson, CL
    Williams, E
    Carmen, S
    Smith, R
    Roschke, V
    Hilbert, DM
    Vaughan, TJ
    Albert, VR
    [J]. ARTHRITIS AND RHEUMATISM, 2003, 48 (11): : 3253 - 3265
  • [9] Bhatia A, 1998, IMMUNOLOGY, V94, P56
  • [10] Bm1-Bm5 classification of peripheral blood B cells reveals circulating germinal center founder cells in healthy individuals and disturbance in the B cell subpopulations in patients with primary Sjogren's syndrome
    Bohnhorst, JO
    Bjorgan, MB
    Thoen, JE
    Natvig, JB
    Thompson, KM
    [J]. JOURNAL OF IMMUNOLOGY, 2001, 167 (07) : 3610 - 3618